Author

Daniél V. Møller

Observed names: D. V. Moller, DANIEL MOLLER, Daniel V Møller, Daniel V. Møller, Daniel Vega Moller, Daniel Vega Møller, Daniél Møller, Daniél V Møller, Daniél Vega Møller

Institutions: University of Copenhagen, Mayo Clinic, University of Leicester, Novo Nordisk (Denmark), University of Manchester, NIHR Leicester Biomedical Research Centre, University of Missouri–Kansas City, University of Glasgow

Observed institutions: Statens Serum Institut, University of Copenhagen, Mayo Clinic, Baker Heart and Diabetes Institute, University of Leicester, Novo Nordisk (Denmark), Glostrup Hospital, Copenhagen University Hospital, Gentofte Hospital, Rigshospitalet, University of Manchester, National Institute for Health and Care Research, Zealand Pharma (Denmark), Capital Region of Denmark, NIHR Leicester Biomedical Research Centre, University of Missouri–Kansas City, University of Glasgow

OpenAlex ID: A5111525200

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity

2023 · Mikhail N. Kosiborod, Steen Z. Abildstrøm, et al. · New England Journal of Medicine · 1,647

PDF

Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes

2024 · Mikhail N. Kosiborod, Mark C. Petrie, et al. · New England Journal of Medicine · 747

Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials

2024 · Javed Butler, Sanjiv J Shah, et al. · The Lancet · 381

Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial

2023 · Barry A. Borlaug, Dalane W. Kitzman, et al. · Nature Medicine · 213

PDF

Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers

2022 · Caroline Holm Nørgaard, Sarah Friedrich, et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions · 206

PDF

Mutations in sodium channel β-subunit SCN3B are associated with early-onset lone atrial fibrillation

2010 · Morten S. Olesen, Thomas Jespersen, et al. · Cardiovascular Research · 127

Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog

2017 · Ulrike Hövelmann, Britta Væver Bysted, et al. · Diabetes Care · 114

Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype

2023 · Mikhail N. Kosiborod, Steen Z. Abildstrøm, et al. · JACC Heart Failure · 97

Usefulness of Soluble Urokinase Plasminogen Activator Receptor to Predict Repeat Myocardial Infarction and Mortality in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Intervention

2012 · Stig Lyngbæk, Jacob L. Marott, et al. · The American Journal of Cardiology · 95

The role of sarcomere gene mutations in patients with idiopathic dilated cardiomyopathy

2009 · Daniel Vega Møller, Paal Skytt Andersen, et al. · European Journal of Human Genetics · 89

PDF

Heart failure etiology impacts survival of patients with heart failure

2010 · Redi Pecini, Daniel Vega Møller, et al. · International Journal of Cardiology · 70

Relative Atrial Natriuretic Peptide Deficiency and Inadequate Renin and Angiotensin II Suppression in Obese Hypertensive Men

2013 · Camilla L. Asferg, Søren J. Nielsen, et al. · Hypertension · 58

Soluble Urokinase Plasminogen Activator Receptor for Risk Prediction in Patients Admitted with Acute Chest Pain

2013 · Stig Lyngbæk, Charlotte Andersson, et al. · Clinical Chemistry · 57

Long-term prognostic importance of resting heart rate in patients with left ventricular dysfunction in connection with either heart failure or myocardial infarction: The DIAMOND study

2008 · Emil Loldrup Fosbøl, Marie Seibæk, et al. · International Journal of Cardiology · 57

Liraglutide and semaglutide: Pooled post hoc analysis to evaluate risk of dementia in patients with type 2 diabetes

2020 · Clive Ballard, Caroline Holm Nørgaard, et al. · Alzheimer s & Dementia · 25

Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14

2019 · Richard E. Pratley, Mansoor Husain, et al. · Cardiovascular Diabetology · 25

PDF

Metabolic Rather Than Body Composition Measurements Are Associated With Lower Serum Natriuretic Peptide Concentrations in Normal Weight and Obese Men

2013 · C. L. Asferg, S. J. Nielsen, et al. · American Journal of Hypertension · 18

Quantitative assessment of left ventricular systolic wall thickening using multidetector computed tomography

2008 · Thomas S. Kristensen, Klaus F. Kofoed, et al. · European Journal of Radiology · 18

Differential Prognostic Importance of QRS Duration in Heart Failure and Acute Myocardial Infarction Associated with Left Ventricular Dysfunction

2007 · Emil Loldrup Fosbøl, Marie Seibæk, et al. · European Journal of Heart Failure · 13

PDF

Hereditary Hemochromatosis (HFE) genotypes in heart failure: Relation to etiology and prognosis

2010 · EchoCardiography and Heart Outcome Study (ECHOS) investigators, Daniel V Møller, et al. · BMC Medical Genetics · 11

PDF

Long QT syndrome - a genetic cardiac channelopathy.

2010 · Magdalena A Szeliga, Paula L Hedley, et al. · PubMed · 7

Insulin analogues dosing and costs - comparing real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients

2012 · Marie Jakobsen, Mette Dalsgaard, et al. · BMC Endocrine Disorders · 6

PDF

Mutation analysis of the candidate genes SCN1B-4B, FHL1, and LMNA in patients with arrhythmogenic right ventricular cardiomyopathy

2012 · Lena Refsgaard, Morten Salling Olesen, et al. · Applied & Translational Genomics · 5

PDF

Substantial Myocardial Abscess in an Immunocompromised Patient: Fatal Outcome After Coagulase-negative Staphylococcal Native Valve Infection

2007 · Daniel Vega Moller, Niels Eske Bruun · Journal of the American Society of Echocardiography · 5

PDF

Obese Hypertensive Men Have Plasma Concentrations of C-Reactive Protein Similar to That of Obese Normotensive Men

2014 · Camilla L. Asferg, Ulrik B. Andersen, et al. · American Journal of Hypertension · 4

Works count: 33

Citation count: 4,098

H-index: 18

I10-index: 20